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Children with cystic ﬁbrosis (CF) often take proton pump inhibitors (PPIs), which helps improve eﬃcacy of fat absorption with
pancreatic enzyme replacement therapy. However, PPI use is known to be associated with Clostridium diﬃcile-(C. diﬀ-) associated
diarrhea (CDAD). We retrospectively evaluated the incidence of C. diﬀ infection from all pediatric hospital admissions over a
5-year period at a single tertiary children’s hospital. We found signiﬁcantly more C. diﬀ-positive stool tests in hospitalized patients
with CF compared to patients with no diagnosis of CF. However, use of a PPI was not associated with an increased risk of CDAD
in hospitalized CF patients. In summary, C. diﬀ infection is more common in hospitalized pediatric CF patients although PPI use
may not be a risk factor for CDAD development in this patient population.
1.Introduction
Cystic ﬁbrosis (CF) is a hereditary multiorgan disease that
aﬀects approximately 30,000 people in the United States
[1]. Mutation in the cystic ﬁbrosis transmembrane regulator
(CFTR)generesultsin impaired iontransport withinepithe-
lial cells and leads to mucosal obstruction of exocrine glands,
such as in the pancreas [1]. Subsequent hyperviscosity of
pancreatic enzyme secretions obstructs the pancreatic ducts
and lead to pancreatic ﬁbrosis with poor fat and protein
absorption. As a result, CF patients receive pancreatic en-
zyme replacement therapy (PERT) to aid in fat absorption.
Proton pump inhibitors (PPIs) can improve fat absorption
and decrease symptoms of steatorrhea in CF patients by
inhibiting breakdown of PERT by gastric acid [2, 3].
Therefore, PPI usage is widely used in the CF population [2–
5].
Chronic antibiotic use, prolonged hospitalization, and
acid-suppressive agents (such as PPIs) are risk factors for
developing infectionwithClostridiumdiﬃcile(C.diﬀ)[6,7].
C. diﬀ can manifest from asymptomatic colonization of the
gastrointestinal tract to life-threatening conditions such as
pseudomembranous colitis and toxic megacolon [6]. Gastric
acidity protects the host against ingested pathogens, and this
protection is impaired when acid production is suppressed
[7]. Several studies have demonstrated that acid suppression
therapy with PPIs may increase the risk of C. diﬀ-associated
diarrhea (CDAD) [8–12]. We retrospectively evaluated the
prevalence of C. diﬀ infection in the pediatric CF population
at a single pediatric tertiary medical center and tried to de-2 Gastroenterology Research and Practice
Table 1: Positive C. diﬀ tests for inpatient pediatric patients.
Total tests 8543
All tests in patients with no CF 8302
Positive tests in patients with no CF 1659 (20%)∗
All tests in CF patients 241
Positive tests in patients with CF 86 (35.7%)∗
∗P < 0.05.
termine if use of PPI increased the risk of infection in this
patient population.
2. Methods
A retrospective chart review occurred over a 5-year period
(January 1, 2005, through December 31, 2010) to determine
how many tests had been performed for C. diﬀ during
all inpatient admissions. This data was obtained from the
Intermountain Electronic Data Warehouse, Intermountain
Primary Children’s Medical Center electronic medical record
and microbiology lab data. Testing for C. diﬀ occurred by
toxin ELISA assay or by toxin DNA analysis (Illumigene,
Meridian Bioscience, Inc., Cincinnati). Those patients with
CF who had a positive C. diﬀ stool test during a hospital
admission were further analyzed using the Cystic Fibrosis
Foundation Patient Registry and the electronic medical
record to determine if they had been on a PPI during this
admission. Chi-square testing was used to compare preva-
lence of C. diﬀ in hospitalized patients with and without CF,
and relative risk analysis was used to determine the risk of
C. diﬀ in CF patients receiving a PPI [13]. The project was
approved by the University of Utah Investigational Review
Board.
3. Results
During the 5-year study period, 8543 tests for C. diﬀ were
performed on hospitalized patients (8302 non-CF controls
and 241 CF cases). The prevalence of C. diﬀ in controls
versus CF patients was statistically signiﬁcant (P < 0.05) with
the period prevalence of C. diﬀ infection being 20% (n =
1659) and 35.7% (n = 86), respectively. We were only able to
determinethetotalnumberofC.diﬀ teststhatoccurred,and
testing may have occurred more than once in some patients
(Table 1).
Next, we evaluated all CF patients who were hospitalized
during this time period using the Cystic Fibrosis Foundation
Patient Registry to determine which patients were on a PPI.
We found 215 total patients which were diﬀerent than the
total number of patients found using the electronic medical
record (241 patients). Of these 215 patients, 140 were on no
PPI and 57 of these patients (40.7%) had CDAD. There were
75 patients who were on a PPI, and 30 patients (40%) had
CDAD. A relative risk analysis was not signiﬁcant suggesting
that the risk of developing CDAD in CF patients was equal
regardless of PPI exposure (Table 2).
Table 2: CDAD in CF patients with/without PPI use.
Total CF patients admitted to hospital 215
CF patients on PPI and CDAD 30 (40%)∗
CF patients on PPI and no CDAD 45
CF patients on no PPI and CDAD 57 (40.7%)∗
C Fp a t i e n to nn oP P Ia n dn oC D A D 8 3
∗Relative risk 0.98 (95% conﬁdence interval 0.698 to 1.382), P = 0.91.
4. Discussion
This retrospective study evaluated both the prevalence of
C. diﬀ infection in CF pediatric patients during inpatient
admission compared to patients without CF and the risk
of CDAD in CF patients receiving a PPI. We found that
signiﬁcantly more patients had positive C. diﬀ testing during
hospital admission with CF compared to non-CF patients.
UnlikeCFpediatricpatients,thetypicalhospitalizedpatients
with CDAD in the United States hospitals are elderly, female,
and have associated sepsis [14]. Antibiotic use is also asso-
ciated with CDAD in hospitalized patients [15].
It is known that the asymptomatic carriage rate of C. diﬀ
in CF can be as high as 50%, and associated factorsleading to
CDAD in hospitalized CF patients potentially could include
risk factors such as recurrent hospitalization, prolonged
intravenous antibiotic use, and lack of colonization with
Lactobacillus species and other bacteria that may have
inhibitory eﬀects on the growth of C. diﬀ [16–18]. Other
diseases associated with C. diﬀ, such as Crohn’s disease,
occur more frequently in CF patients [19]. Additionally, CF
genotypes, such as N1303K, are associated with more severe
clinical presentations of CDAD [20].
PPI use has been associated with an increased risk of
CDAD,especiallyintheelderly[21].Theeﬀectispresumable
due to gastric acid inhibition by PPIs, and the risk of
infection is increased with escalating PPI dosing [22]. In-
terestingly, we saw no increased incidence of CDAD in CF
pediatric patients, regardless of PPI usage status. The cause
of this ﬁnding is unknown. A prior study looking at the
risk of developing CDAD in a community setting did not
ﬁnd PPI usage associated with an increased risk of CDAD;
however, otherproposed risk factorsfordisease transmission
in this population included person-to-person transmission
and remote health care exposures [23]. Bacterial overgrowth
isnotalwaysassociatedwithintestinalinﬂammationinsome
CF patients, suggesting that there may be other microbiome,
genetic, or inﬂammatory pathways that may explain our
ﬁnding [24]. It is the clinical practice at our institution
to place all CF patients on Lactobacillus GG at time of
admission and throughoutthe intravenous antibiotic course.
Thistreatmentisnottypicallycontinueduponcompletionof
anantibiotictreatmentunlessthepatienthasbeendiagnosed
withCDAD during hospitalization. However,itisnotknown
ifsuchtherapyiseﬀectiveinpreventingCDADinthispatient
population [25].
There are weaknesses in this study. This study is retro-
spective and consists of data from a single tertiary medical
center. In our review of the electronic medical record ofGastroenterology Research and Practice 3
all pediatric inpatient admissions, we could not determine
if testing for C. diﬀ occurred because of CDAD, although
asymptomatic hospitalized patients presumably would not
be tested for this pathogen. However, we were able to
determineCDADinhospitalizedCFpatientsusingtheCystic
Fibrosis Foundation Patient Registry. Finally, we did not
evaluate for other potential causes that would explain the
lack of diﬀerence in CDAD regardless of PPI use in the CF
population, although we did evaluate a large number of




pediatric patients with CF compared to patients hospitalized
forothermedicalreasons.PPIusebyCFpatientsappearsnot
to be associated with an increased risk of developing CDAD.
We encourage judicious use of antibiotics as well as simple
techniques in preventing disease transmission, such as good
handwashing to prevent CDAD in CF pediatric patients. We
recommend a prospective, multicenter study to corroborate
these ﬁndings and to determine what speciﬁc risk factors in
the CF pediatric population predispose to C. diﬀ infection
such as CF genotype, length of PPI usage, patient age, and
presence of other comorbidities such as inﬂammatory bowel
disease.
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